tinlorafenib   Click here for help

GtoPdb Ligand ID: 12096

Synonyms: ARRY-461 | ARRY461 | PF-07284890 | PF07284890
Compound class: Synthetic organic
Comment: We obtained the chemical structure for tinlorafenib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as an antineoplastic. The INN indicates that it is a RAF kinase inhibitor. Further investigations revealed that tinlorafenib has the synonyms PF-07284890 and ARRY-461, that it inhibits BRAF and CRAF, and that it is orally bioavailable and able to cross the blood-brain barrier [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 101.47
Molecular weight 456.08
XLogP 4.21
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES FCCCS(=O)(=O)Nc1ccc(c(c1Cl)Nc1ccc2c(c1C)c(=O)n(cn2)C)F
Isomeric SMILES Clc1c(ccc(c1Nc1c(c2c(=O)n(cnc2cc1)C)C)F)NS(=O)(=O)CCCF
InChI InChI=1S/C19H19ClF2N4O3S/c1-11-13(6-7-14-16(11)19(27)26(2)10-23-14)24-18-12(22)4-5-15(17(18)20)25-30(28,29)9-3-8-21/h4-7,10,24-25H,3,8-9H2,1-2H3
InChI Key VVLVISDSGRHLMB-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
PF-07284890 has advanced to clinical trial to determine its efficacy against advanced solid tumours with BRAF V600 mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04543188 A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement Phase 1 Interventional Pfizer
NCT05349864 A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults Phase 1 Interventional Pfizer